Search results for "Current analysis"

showing 2 items of 2 documents

Acute Effect of Citrulline Malate on Repetition Performance During Strength Training: A Systematic Review and Meta-Analysis.

2021

Citrulline malate (CitMal) is a dietary supplement that is suggested to enhance strength training performance. However, there is conflicting evidence on this matter. Thus, the purpose of this meta-analysis was to determine whether supplementing with CitMal prior to strength training could increase the total number of repetitions performed before reaching voluntary muscular failure. A systematic search was conducted wherein the inclusion criteria were double-blind, placebo-controlled studies in healthy participants that examined the effect of CitMal on repetitions to failure during upper body and lower body resistance exercises. The Hedges’s g standardized mean differences (SMD) between the …

AdultMalemedicine.medical_specialtyTime FactorsStrength trainingCitrulline malateDietary supplementMalatesMedicine (miscellaneous)Acute effectPerformance-Enhancing SubstancesPlacebo03 medical and health sciencesYoung Adult0302 clinical medicineBiasDouble-Blind MethodMedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and Dieteticsbusiness.industryUpper bodyResistance Training030229 sport sciencesGeneral MedicinePhysical Functional PerformanceCurrent analysisMeta-analysisPhysical therapyPhysical EnduranceCitrullineFemalebusinessInternational journal of sport nutrition and exercise metabolism
researchProduct

POS1021 THE PsABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INH…

2021

Background:There are still unmet needs in the treatment of psoriatic arthritis (PsA), including in terms of treatment persistence, which is a function of effectiveness, safety and patient satisfaction. Ustekinumab (UST) was the first new biologic drug to be developed for the treatment of PsA after tumour necrosis factor inhibitors (TNFi).Objectives:To compare treatment persistence, effectiveness and safety of UST and TNFi in Italian patients within the PsABio cohort.Methods:PsABio (NCT02627768) is an observational study of 1st/2nd/3rd-line UST or TNFi treatment in PsA in 8 European countries. The current analysis set includes 222 eligible patients treated in 15 Italian centres, followed to …

medicine.medical_specialtybusiness.industryImmunologySignificant differenceClinical diseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCurrent analysisUnmet needsPsoriatic arthritisRheumatologyInternal medicineUstekinumabTreatment persistenceImmunology and AllergyMedicineIn patientbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct